Gerresheimer with a solid start of financial year 2014

Duesseldorf (ots) -

- cross reference: The full press release including tables is
available at:
http://www.presseportal.de/dokumente abrufbar -

- Revenues up 0.3% to EUR 297.5m (+3.2% at constant exchange
rates)
- Adjusted EBITDA rises 3.3% to EUR 47.6m (EUR 49.1m at constant
exchange rates)
- Net income grows by 0.8% to EUR 10.3m
- Adjusted earnings per share up 5.6% to EUR 0.38
- Guidance for financial year 2014 confirmed

Gerresheimer AG, one of the leading partners to the pharma and
healthcare industry worldwide, began financial year 2014 with a solid
start. "I am satisfied with our performance in the first quarter of
2014. Our expectation is unchanged that we will meet our targets for
2014. We will continue to invest in promising projects in Europe, the
Americas and emerging markets to lay the basis for further profitable
growth," said Uwe Röhrhoff, CEO of Gerresheimer AG.

Gerresheimer generated revenues of EUR 297.5m in the first quarter
of financial year 2014 (December 1, 2013 to November 30, 2014),
marking 0.3% revenue growth on the prior-year quarter. At constant
exchange rates, revenues came to EUR 304.2m, representing growth of
3.2%. As expected, the Primary Packaging Glass and Life Science
Research (laboratory glassware) divisions experienced a decline in
demand during the first month of the first quarter due to destocking
by a number of North American pharmaceutical customers. Demand for
cosmetic glass was likewise slow at the beginning of the first
quarter. There were already clear signs of improvement by the end of
the quarter. Revenues went up substantially on customer-specific
drug-delivery devices such as insulin pens, inhalers, prefillable
syringe systems and pharmaceutical plastic packaging.

The Company generated adjusted EBITDA of EUR 47.6m in the first
quarter of 2014, an increase of 3.3% on the prior-year figure. The
adjusted EBITDA margin was 16% in the first quarter, half a
percentage point up on the 15.5% prior-year figure. The margin showed
a slight improvement across all three divisions. Net income went up
by 0.8% to EUR 10.3m. Adjusted earnings per share, at EUR 0.38,
exceeded the EUR 0.36 recorded in the prior-year quarter.

As planned, Gerresheimer incurred capital expenditure of EUR 21.7m
in the first quarter. Capital expenditure focused on adding
production capacity for medical plastic systems such as insulin pens
and inhalers in Horsovsky Tyn, Czech Republic, and Peachtree City,
USA.

Outlook

As before, the Company anticipates revenue growth of 4% to 6% at
constant exchange rates for financial year 2014. Gerresheimer
continues to expect adjusted EBITDA to be in a range of between EUR
250m and EUR 265m at constant exchange rates. Capital expenditure in
financial year 2014 will be on a par with the preceding financial
year, representing some 9% to 10% of exchange rate adjusted revenues.

The Q1 report is online available here:
http://gerresheimer.com/en/investor-relations/reports

The online annual report 2013 is available here:
http://annualreport2013.gerresheimer.com

Pressekontakt:
Gerresheimer AG
Benrather Strasse 18 - 20
40213 Düsseldorf
Germany

Jens Kürten
Director Corporate Communication & Marketing
Telephone +49 211 6181-250
Fax +49 211 6181-241
E-Mail j.kuerten@gerresheimer.com
Internet www.gerresheimer.com